Meta-analysis of cardiovascular events after CAR-T therapy for advanced hematologic malignancies

The frequency and clinical phenotypes of cardiotoxic evens in chimeric antigen receptor (CAR) T-cell recipients remain poorly understood given that landmark approval trials typically exclude patients with high-risk cardiovascular profiles and data from nontrial settings are scarce. A meta-analysis of observational studies summarized the prevalence of adverse cardiovascular events among adults receiving CAR T-cell therapies for advanced hematologic malignancies. In this meta-analysis of 13 studies comprising 1528 CAR T-cell recipients, a low pooled prevalence of serious cardiac events, such as ventricula arrhytmia, myocardial infarction, and cardiovascular death, was observed. The most commonly observed complications were left ventricular dysfunction and supraventricular arrhytmia. The authors conclude that cardiovascular surveillance strategies in CAR T-cell recipients should focus on decreases in ejection fraction and supraventricular arrhytmia.